Advertisement
Screener

Rein Therapeutics, Inc. (RNTX) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Rein Therapeutics, Inc. Financing Cash Flow

Rein Therapeutics, Inc. (RNTX) reported Financing Cash Flow of $52.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14

  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $47.81M, a 914.75% increase year-over-year.
  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $4.65M, a 530.62% increase year-over-year.
  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.40M, a 240400.00% increase year-over-year.
  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.90M.
  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $9.76M, a 45.25% decline from fiscal 2024.
  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $17.82M, a 12.81% increase from fiscal 2023.
  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $15.79M.
  • Rein Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $55.66M, a 252.26% increase from fiscal 2020.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30$47.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$52.47M
10-Q · filed 2026-08-14
$54.87M
derived: sum of 3 quarters · filed 2026-08-14
$56.77M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$4.65M
10-Q · filed 2026-05-15
$7.06M
derived: sum of 2 quarters · filed 2026-05-15
$8.96M
derived: sum of 3 quarters · filed 2026-05-15
$13.67M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$2.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$4.30M
derived: sum of 2 quarters · filed 2026-03-26
$9.02M
derived: sum of 3 quarters · filed 2026-08-14
$9.76M
10-K · filed 2026-03-26
2025-09-30$1.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$6.61M
derived: sum of 2 quarters · filed 2026-08-14
$7.35M
10-Q · filed 2025-11-14
$7.35M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$4.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$5.45M
10-Q · filed 2026-08-14
$5.45M
derived: sum of 3 quarters · filed 2026-08-14
$5.00M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$738.00K
10-Q · filed 2026-05-15
$739.00K
derived: sum of 2 quarters · filed 2026-05-15
$293.00K
derived: sum of 3 quarters · filed 2026-05-15
$18.56M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
-$445.00K
derived: sum of 2 quarters · filed 2026-03-26
$17.82M
derived: sum of 3 quarters · filed 2026-03-26
$17.82M
10-K · filed 2026-03-26
2024-09-30-$446.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$17.82M
derived: sum of 2 quarters · filed 2025-11-14
$17.82M
10-Q · filed 2025-11-14
$33.61M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$18.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$18.26M
10-Q · filed 2025-08-14
$34.06M
derived: sum of 3 quarters · filed 2025-08-14
$34.06M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$0.00
10-Q · filed 2025-05-15
$15.79M
derived: sum of 2 quarters · filed 2025-05-15
$15.79M
derived: sum of 3 quarters · filed 2025-05-15
2023-12-31$15.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07
$15.79M
derived: sum of 2 quarters · filed 2025-04-07
$15.79M
10-K · filed 2025-04-07
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$0.00
10-Q · filed 2024-11-14
2023-06-30$0.00
10-Q · filed 2024-08-14
2021-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
$27.00K
derived: sum of 2 quarters · filed 2023-03-20
$53.00K
derived: sum of 3 quarters · filed 2023-03-20
$55.66M
10-K · filed 2023-03-20
2021-09-30$26.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
$52.00K
derived: sum of 2 quarters · filed 2022-11-01
$55.66M
10-Q · filed 2022-11-01
$59.90M
derived: sum of 4 quarters · filed 2022-11-01
2021-06-30$26.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
$55.63M
10-Q · filed 2022-08-15
$59.87M
derived: sum of 3 quarters · filed 2022-08-15
$60.17M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$55.60M
10-Q · filed 2022-05-05
$59.85M
derived: sum of 2 quarters · filed 2022-05-05
$60.14M
derived: sum of 3 quarters · filed 2022-05-05
$71.40M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$4.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28
$4.54M
derived: sum of 2 quarters · filed 2022-03-28
$15.80M
derived: sum of 3 quarters · filed 2022-03-28
$15.80M
10-K · filed 2022-03-28
2020-09-30$298.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$11.56M
derived: sum of 2 quarters · filed 2021-11-12
$11.56M
10-Q · filed 2021-11-12
$11.54M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$11.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
$11.26M
10-Q · filed 2021-08-11
$11.24M
derived: sum of 3 quarters · filed 2021-08-11
$11.19M
derived: sum of 4 quarters · filed 2021-08-11
2020-03-31$0.00
10-Q · filed 2021-05-11
-$15.00K
derived: sum of 2 quarters · filed 2021-05-11
-$66.00K
derived: sum of 3 quarters · filed 2021-05-11
$23.80M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31-$15.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24
-$66.00K
derived: sum of 2 quarters · filed 2021-03-24
$23.80M
derived: sum of 3 quarters · filed 2021-03-24
$23.96M
10-K · filed 2021-03-24
2019-09-30-$51.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
$23.81M
derived: sum of 2 quarters · filed 2020-11-12
$23.98M
10-Q · filed 2020-11-12
$25.26M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$23.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05
$24.03M
10-Q · filed 2020-08-05
$25.31M
derived: sum of 3 quarters · filed 2020-08-05
$26.52M
derived: sum of 4 quarters · filed 2020-08-05
2019-03-31$165.00K
10-Q · filed 2020-05-11
$1.44M
derived: sum of 2 quarters · filed 2020-05-11
$2.65M
derived: sum of 3 quarters · filed 2020-05-11
$2.66M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$1.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30
$2.49M
derived: sum of 2 quarters · filed 2020-03-30
$2.50M
derived: sum of 3 quarters · filed 2020-03-30
$2.52M
10-K · filed 2020-03-30
2018-09-30$1.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
$1.22M
derived: sum of 2 quarters · filed 2019-11-07
$1.24M
10-Q · filed 2019-11-07
$994.00K
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30$12.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$28.00K
10-Q · filed 2019-08-06
-$216.00K
derived: sum of 3 quarters · filed 2019-08-06
$50.49M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31$16.00K
10-Q · filed 2019-05-08
-$228.00K
derived: sum of 2 quarters · filed 2019-05-08
$50.47M
derived: sum of 3 quarters · filed 2019-05-08
2017-12-31-$244.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29
$50.46M
derived: sum of 2 quarters · filed 2019-03-29
$50.59M
10-K · filed 2019-03-29
2017-09-30$50.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$50.84M
10-Q · filed 2018-11-07
2017-06-30$133.00K
10-Q · filed 2018-08-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
HYPERION DEFI, INC. (HYPD)United States$0.065B
XBiotech Inc. (XBIT)United States$0.066B-1.56
Skye Bioscience, Inc. (SKYE)United States$0.061B-0.48
CalciMedica, Inc. (CALC)United States$0.061B-1.42
TALPHERA, INC. (TLPH)United States$0.060B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58